

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 December 2021 (02.12.2021)



(10) International Publication Number
WO 2021/243057 A1

(51) International Patent Classification:

C07K 14/00 (2006.01) *A61K 38/16* (2006.01)
A61K 45/00 (2006.01) *A61K 38/20* (2006.01)
A61K 38/00 (2006.01) *C07K 14/005* (2006.01)

(21) International Application Number:

PCT/US2021/034580

(22) International Filing Date:

27 May 2021 (27.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/031,186 28 May 2020 (28.05.2020) US



(71) Applicant: **THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY** [US/US];
Office of the General Counsel, Building 170, Third Floor,
Main Quad, P.O. Box 203, Stanford, California 94305-2038
(US).

(72) Inventors: **GARCIA, Kenan Christopher**; Trustees/ Leland Stanford Junior University, 3000 El Camino Real, Building 5, Suite 300, Palo Alto, California 94306 (US).
SAXTON, Robert Andrew; Trustees/ Leland Stanford Junior University, 3000 El Camino Real, Building 5, Suite 300, Palo Alto, California 94306 (US).

(74) Agent: **SHIEH-NEWTON, Terri** et al.; One Financial Center, Boston, Massachusetts 02111 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: ENGINEERED INTERLEUKIN-10 POLYPEPTIDES AND USES THEREOF



(57) Abstract: The present disclosure relates generally to compositions and methods for modulating signal transduction mediated by interleukin-10 (IL-10). In particular, the disclosure provides novel IL-10 polypeptide variants with altered binding affinity to interleukin-10 receptor subunit beta (IL-10Rβ). Also provided are compositions and methods useful for producing such IL-10 polypeptide variants, as well as methods for modulating IL-10-mediated signaling, and/or for the treatment of conditions associated with the perturbation of signal transduction mediated by IL-10.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*